Massimo Breccia


Ontology type: schema:Person     


Person Info

NAME

Massimo

SURNAME

Breccia

Publications in SciGraph latest 50 shown

  • 2021-05-17 Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study in LEUKEMIA
  • 2021-03-15 American Society of Hematology 2020 Podcast Collection: CML in ADVANCES IN THERAPY
  • 2021-03-07 Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients in ANNALS OF HEMATOLOGY
  • 2021-01-07 Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA) in ANNALS OF HEMATOLOGY
  • 2021-01-03 Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib in ANNALS OF HEMATOLOGY
  • 2020-10-22 Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors in CLINICAL DRUG INVESTIGATION
  • 2020-08-27 Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab in ANNALS OF HEMATOLOGY
  • 2020-08-25 COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey in LEUKEMIA
  • 2020-08-19 Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience in ANNALS OF HEMATOLOGY
  • 2020-07-03 How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey in LEUKEMIA
  • 2020-06-25 High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2020-06-18 Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey in LEUKEMIA
  • 2020-06-08 Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study in BLOOD CANCER JOURNAL
  • 2020-05-30 Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors in ANNALS OF HEMATOLOGY
  • 2020-05-28 Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients in ANNALS OF HEMATOLOGY
  • 2020-05-04 Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors in LEUKEMIA
  • 2020-02-21 The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index in LEUKEMIA
  • 2019-12-12 Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice in ANNALS OF HEMATOLOGY
  • 2019-12-05 Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2019-10-14 Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial in LEUKEMIA
  • 2019-09-18 The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review in BONE MARROW TRANSPLANTATION
  • 2019-09-02 Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy in LEUKEMIA
  • 2019-08-07 Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline in ANNALS OF HEMATOLOGY
  • 2019-06-14 Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis in ANNALS OF HEMATOLOGY
  • 2019-06-05 Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice in ANNALS OF HEMATOLOGY
  • 2019-05-11 Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life in ANNALS OF HEMATOLOGY
  • 2019-05-01 Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice in ANNALS OF HEMATOLOGY
  • 2018-12-20 Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia in LEUKEMIA
  • 2018-12-04 Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib in ANNALS OF HEMATOLOGY
  • 2018-06-27 Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy in ANNALS OF HEMATOLOGY
  • 2018-06-10 Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia in ANNALS OF HEMATOLOGY
  • 2018-05-27 Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events in ANNALS OF HEMATOLOGY
  • 2018-04-19 Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice in ANNALS OF HEMATOLOGY
  • 2018-03-08 Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project in QUALITY OF LIFE RESEARCH
  • 2018-03-06 Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia in CURRENT ONCOLOGY REPORTS
  • 2018-02-22 Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment in ANNALS OF HEMATOLOGY
  • 2018-01-23 Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option in CLINICAL DRUG INVESTIGATION
  • 2017-10-18 Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients in HEALTH AND QUALITY OF LIFE OUTCOMES
  • 2017-10-02 Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series in ANNALS OF HEMATOLOGY
  • 2017-09-26 Special Situations in APL in ACUTE PROMYELOCYTIC LEUKEMIA
  • 2017-06-12 Recovering from chronic myeloid leukemia: the patients’ perspective seen through the lens of narrative medicine in QUALITY OF LIFE RESEARCH
  • 2017-05-26 A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts in LEUKEMIA
  • 2016-11-26 Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN in ANNALS OF HEMATOLOGY
  • 2016-09-30 Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion in ANNALS OF HEMATOLOGY
  • 2016-07-23 Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies in SUPPORTIVE CARE IN CANCER
  • 2016-06-03 Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis in SUPPORTIVE CARE IN CANCER
  • 2016-05-02 PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy in LEUKEMIA
  • 2016-04-28 European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia in LEUKEMIA
  • 2016-04-19 Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study in ANNALS OF HEMATOLOGY
  • 2016 Chronic Myeloid Leukemia in ENCYCLOPEDIA OF CANCER
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.7841.a", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.415081.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6292.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.6530.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7644.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412725.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4691.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.65499.37", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.1010.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.8484.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417007.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412282.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7605.4", 
            "type": "Organization"
          }
        ], 
        "familyName": "Breccia", 
        "givenName": "Massimo", 
        "id": "sg:person.01367650334.48", 
        "identifier": [
          {
            "name": "orcid_id", 
            "type": "PropertyValue", 
            "value": "0000-0003-1163-6162"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367650334.48", 
          "https://orcid.org/0000-0003-1163-6162"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-01-01T19:56", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/person/person_685.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01367650334.48'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01367650334.48'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01367650334.48'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01367650334.48'


     

    This table displays all metadata directly associated to this object as RDF triples.

    45 TRIPLES      11 PREDICATES      25 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.01367650334.48 schema:affiliation N90034b1fc0454169a8d04d41b2bade04
    2 grid-institutes:grid.1010.0
    3 grid-institutes:grid.412282.f
    4 grid-institutes:grid.412725.7
    5 grid-institutes:grid.415081.9
    6 grid-institutes:grid.417007.5
    7 grid-institutes:grid.4691.a
    8 grid-institutes:grid.6292.f
    9 grid-institutes:grid.6530.0
    10 grid-institutes:grid.65499.37
    11 grid-institutes:grid.7605.4
    12 grid-institutes:grid.7644.1
    13 grid-institutes:grid.8484.0
    14 schema:familyName Breccia
    15 schema:givenName Massimo
    16 schema:identifier Nc1a33fdd2466423882a392dbaf901307
    17 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367650334.48
    18 https://orcid.org/0000-0003-1163-6162
    19 schema:sdDatePublished 2022-01-01T19:56
    20 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    21 schema:sdPublisher N4d1aee4b405b439d847e3f103e7c980a
    22 sgo:license sg:explorer/license/
    23 sgo:sdDataset persons
    24 rdf:type schema:Person
    25 N4d1aee4b405b439d847e3f103e7c980a schema:name Springer Nature - SN SciGraph project
    26 rdf:type schema:Organization
    27 N90034b1fc0454169a8d04d41b2bade04 schema:affiliation grid-institutes:grid.7841.a
    28 sgo:isCurrent true
    29 rdf:type schema:OrganizationRole
    30 Nc1a33fdd2466423882a392dbaf901307 schema:name orcid_id
    31 schema:value 0000-0003-1163-6162
    32 rdf:type schema:PropertyValue
    33 grid-institutes:grid.1010.0 schema:Organization
    34 grid-institutes:grid.412282.f schema:Organization
    35 grid-institutes:grid.412725.7 schema:Organization
    36 grid-institutes:grid.415081.9 schema:Organization
    37 grid-institutes:grid.417007.5 schema:Organization
    38 grid-institutes:grid.4691.a schema:Organization
    39 grid-institutes:grid.6292.f schema:Organization
    40 grid-institutes:grid.6530.0 schema:Organization
    41 grid-institutes:grid.65499.37 schema:Organization
    42 grid-institutes:grid.7605.4 schema:Organization
    43 grid-institutes:grid.7644.1 schema:Organization
    44 grid-institutes:grid.7841.a schema:Organization
    45 grid-institutes:grid.8484.0 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...